CAS: 845714-00-3; 2-(Pyridin-4-yl)-1,5,6,7-Tetrahydro-4H-Pyrrolo[3,2-C]Pyridin-4-One

该化合物是一种化学化合物,其特点是复杂的双环结构,包括pyridine和pyrrolo moiety,该化合物通常具有与七环化合物有关的特性,例如潜在的生物活动,使其对药用化学感兴趣; 环的存在表明它可能从事氢联结并参与各种化学反应,而四氢-pyrrolo结构则有助于其总体稳定性和溶解性; 作为一种盐,它作为盐类,在水中可能比其自由基质形式更容易溶解,在药物应用方面会加强其效用; 化合物可能具有特定的药性特性,有可能在生物系统中起到抑制作用或调节作用,尽管需要进行详细研究,以阐明其确切的行动机制; 安全性和处理预防措施,如同任何化学物质一样,特别是在实验室或工业环境中.

结构式图片

物理性质

MSDS等安全信息

上下游产品

CAS号17570-98-8 2-溴-1-(2-吡啶基)-1... | CAS号50607-30-2 2,4-哌啶二酮 | CAS号845538-60-5 2-[3-(ethoxycar... | CAS号5349-17-7 4-(溴乙酰基)吡啶氢溴酸盐

合成工艺路线路线简述

  • 942425-76-5 = 845714-00-3
    反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Methanol,1,4-Dioxane; 2 H,Rt1.2 Reagents: Ammonia Solvents: Methanol; Neutralized,Rt
    标题:Cdc7 Kinase Inhibitors: Pyrrolopyridinones As Potential Antitumor Agents. 1. Synthesis And Structure-Activity Relationships
    作者:Vanotti,Ermes; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2008 卷标:51(3) 页码:487-501]

    5349-17-7 + 50607-30-2 = 845714-00-3
    反应条件:1.1 Reagents: Ammonium Acetate Solvents: Ethanol; 1 H,Rt
    标题:Pyrrolopyridine Inhibitors Of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (Mk-2)
    作者:Anderson,David R.; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2007 卷标:50(11) 页码:2647-2654]

    50607-30-2 + 2712862-17-2 = 845714-00-3
    反应条件:1.1 Reagents: Ammonium Acetate Solvents: Ethanol; Overnight,Rt
    标题:Development Of Dihydropyrrolopyridinone-Based Pkn2/prk2 Chemical Tools To Enable Drug Discovery
    作者:Scott,Fiona; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2022 卷标:60]

    5349-17-7 + 845267-78-9 = 845714-00-3
    反应条件:1.1 Reagents: Ammonium Acetate Solvents: Ethanol; 16 H,Rt2.1 Reagents: Hydrochloric Acid Solvents: Methanol,1,4-Dioxane; 2 H,Rt2.2 Reagents: Ammonia Solvents: Methanol; Neutralized,Rt
    标题:Cdc7 Kinase Inhibitors: Pyrrolopyridinones As Potential Antitumor Agents. 1. Synthesis And Structure-Activity Relationships
    作者:Vanotti,Ermes; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2008 卷标:51(3) 页码:487-501]

    837381-84-7 = 845714-00-3
    反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Dichloromethane,Water2.1 Reagents: Ammonium Acetate Solvents: Ethanol; 1 H,Rt
    标题:Pyrrolopyridine Inhibitors Of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (Mk-2)
    作者:Anderson,David R.; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2007 卷标:50(11) 页码:2647-2654]

    2033-24-1 + 3303-84-2 = 845714-00-3
    反应条件:1.1 Reagents: 4-(Dimethylamino)Pyridine,1-Ethyl-3-(3′-Dimethylaminopropyl)Carbodiimide Hydrochloride Solvents: Dichloromethane; Overnight,Rt1.2 Solvents: Ethyl Acetate; 4 H,Reflux2.1 Reagents: Ammonium Acetate Solvents: Ethanol; 16 H,Rt3.1 Reagents: Hydrochloric Acid Solvents: Methanol,1,4-Dioxane; 2 H,Rt3.2 Reagents: Ammonia Solvents: Methanol; Neutralized,Rt
    标题:Cdc7 Kinase Inhibitors: Pyrrolopyridinones As Potential Antitumor Agents. 1. Synthesis And Structure-Activity Relationships
    作者:Vanotti,Ermes; Et Al
    参考文献:Journal Of Medicinal Chemistry 日期:2008 卷标:51(3) 页码:487-501
📜2-[3-(Ethoxycarbonyl)-5-Pyridin-4-Yl-1H-Pyrrol-2-Yl]Ethanaminium Chloride置于potassium Carbonate体系中,用 乙醇 作为反应溶剂,化学反应 16.0H,反应生成 1,5,6,7-四氢-2-(4-吡啶基)-4H-吡咯并[3,2-C]吡啶-4-酮
参考文献: Pyridylpyrrole Derivatives Active As Kinase Inhibitors[fr] Derives De Pyridylpyrrole Comme Inhibiteurs De Kinase
标题: Pyridylpyrrole Derivatives Active As Kinase Inhibitors[fr] Derives De Pyridylpyrrole Comme Inhibiteurs De Kinase
摘要:公开了化合物的化学式(I)及其药学上可接受的盐,如规范中定义的,以及包含它们的药物组合物;本发明的化合物可能在治疗中对与蛋白激酶活性失调相关的疾病,如癌症,具有用处.

海关参考信息

专利信息


专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Chung YH, Lin CW, Huang HY, Chen SL, Huang HJ, Sun YC, Lee GC, Lee-Chen GJ, Chang YC, Hsieh-Li HM. Targeting Inflammation, PHA-767491 Shows a Broad Spectrum in Protein Aggregation Diseases. J Mol Neurosci. 2020 Jul;70(7):1140-1152. doi: 10.1007/s12031-020-01521-y. Epub 2020 Mar 13. 10(8):2012. doi: 10.3390/biomedicines10082012.
3: Rojas-Prats E, Tosat-Bitrián C, Martínez-González L, Nozal V, Pérez DI, Martínez A. Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. Pharmaceutics. 2021 Jan 28;13(2):180. doi: 10.3390/pharmaceutics13020180.
4: Li W, Zhao XL, Shang SQ, Shen HQ, Chen X. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15(3):196-204. doi: 10.2174/1568009615666150212112753. 36(4):590-600. doi: 10.1007/s10637-017-0557-6. Epub 2018 Jan 3.

合成参考文献


参考文献:10.1158/1535-7163.mct-10-1119
摘要:Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther. 2011 Sep;10(9):1624–34. doi: 10.1158/1535-7163.mct-10-1119.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知